PAR

2.04%

24.0¢ paradigm biopharmaceuticals limited..

I think if you want a punt options are the go as they're...

First 30 Last

Share
Profile

Follow
Weazel

1,410 Posts.

275

06/05/24

21:31

Post #: 73693137
Share

Originally posted by bedger: ↑

And I will only be buying more on a value basis. Its sad, but many on here seem of the opinion a deal does not come without FDA approval and combined with a multitude of poor progress moments in the business since the dreaded Arpil 2023 rambiguous results, its dwindled to its 7 year lows again. It ain;t going to be a Golden Goose, its going to be a Phoenix from the ashes. if a partneship not announced before then.

Unless Paul does announce a partnership within his own recently described timeframes, the share price will indeed be going lower before EOFY. And with no shorts, investors have to look at their peers (or increasing absence of on here) as the part culprits in sellling shares (you have to go back to 2017 the last time it traded these levels (on an adjusted basis after heady $4+ highs in the silliness of early 2020 just before COVID hit).

PAR's prospects looked no better in 2020 of course, but there are a lot more shares on the registry now of course, as @Dungiven duely notes. More to come unless you get that MPS deal you have been alluding to for so long Paul?

I am more buying call options here than shares. Unless PR announces his deal they will continue to deacy into EOFY. If he does, they will surely explode like handgrenades on the news, so downtrodden are the shares of PAR. The prevalence of OA is well known. But talking of options, I'd say the mkt/pricing is only putting a 10% chance at best of PAR of getting to market and being a credible player.

Commiserations to buyers in 2020 through 2023 and those longer-term who did not sell some at least.

Expand

I think if you want a punt options are the go as they're cheap & like you said it could all change very quickly on any good news so the risk to reward ratio is far better

PAR Price at posting: 23.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

First 30 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 24.0¢		Change -0.005(2.04%)		Mkt cap ! $83.98M

Open	High	Low	Value	Volume
25.0¢	25.5¢	24.0¢	$202.2K	814.1K

Buyers (Bids)

No.	Vol.	Price($)
5	181098	24.0¢

Sellers (Offers)

Price($)	Vol.	No.
25.0¢	118621	5

View Market Depth

No.	Vol.	Price($)
2	118000	0.240
4	27745	0.235
1	25000	0.230
2	6262	0.225
6	48629	0.220

Price($)	Vol.	No.
0.250	64601	3
0.255	50000	1
0.260	21333	2
0.265	69367	4
0.270	53000	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)

PAR (ASX) Chart

I think if you want a punt options are the go as they're...

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I think if you want a punt options are the go as they&apos;re...

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I think if you want a punt options are the go as they're...